In-licensing: Central Nervous System/Psychiatric

Latest: Watch here for details of new products and services.

About Us: Pharmalicensing - Partnering solutions for the life sciences
Our Products: Overview; Partnering Search; Company Profiling; Deal Negotiation; PL Intelligence; Reports; Comparison
PL Intelligence: Overview; Industry news; Deals review; Press releases; Articles
Case Studies: See what others think about our service
Newsletter: Partnering update; Key reports; Subscribe
Quick Links: Profile now; Register now; Profiled companies; Featured events; Industry news; PR Newswire; Jobs
Contact Pharmalicensing: Send an email; Call us: +44 1904 520460; Request a callback
RSS Feeds: Keep up to date

Pharmalicensing
is a division of
UTEK Europe Ltd

Up-to-date access to technology licensing opportunities worldwide.

In-licensing
Browse

Licensing opportunities

Displaying 1..7 of 7 - per page
Order by

New Chemical Entities and innovative therapeutic targets

NCEs for innovative therapeutic targets in inflammatory/immunologic diseases. More

Hospital Pharmaceutical Products

Seeking licensing opportunities for the UK hospital market More

Products for CNS disorders

We are looking for products to treat CNS disorders More

Seeking in-licensing opportunities in psychiatry

GOODLIFE Healthcare is looking for in-licensing opportunities in psychiatry More

OTC products for smoking cessation

Products for smoking cessation More

Seeking late stage/launched CNS products, specifically indicated for Parkinson’s disease, dementia, bi-polar disorder and addiction.

Our Spanish based company is looking to acquire late stage or launched CNS products particularly in the areas of Parkinson disease, addiction, bi-polar disorder and schizophrenia. More

Unichem Laboratories Ltd. India seeks opportunities for in-licensing of NDDS and regular versions of pharmaceutical formulations for the high potential Indian market

Unichem wishes to expand its current range of Neuro-Psychiatry (entire CNS area) formulations by partnering with companies and manufacturing / marketing their products under license, for the high potential Indian market. More

Displaying 1..7 of 7 - per page
Order by

Your selection

Therapeutic target: Central Nervous System del; Psychiatric del

Browse By

Industry sector: Animal health; Biotechnology; Diagnostic; Drug delivery; Drug discovery; Medical device; Pharmaceutical; Research tools
Therapeutic target: Addiction; Alcoholism; Anorexia nervosa; Anxiety; Bipolar disorder; Bulimia nervosa; Cocaine addiction; Depression; Mental health (other); Obsessive compulsive disorder; Opioid dependency; Panic disorder; Phobia, social; Post-traumatic stress disorder; Psychosis; Schizophrenia
Development phase: Early Stage; Preclinical; Phase I; Phase I/II; Phase II; Phase III; Phase III/IV; Preregistration; Registered

Clients in focus...

Get the Flash Player to see this rotator.

Press releases: Pharmalicensing current industry press releases.

Products:	Partnering Search	Company Profiling	Deal Negotiation	PL Intelligence	Reports	Comparision
In-licensing:	Latest records	Industry Sector	Therapeutic Target	Search	Profile your company	Pharma partnering
Out-licensing:	Latest records	Industry Sector	Therapeutic Target	Search	Profile your company	Pharma partnering
Companies:	Profiled companies	Industry Sector	Therapeutic Target	Geographic Location	Search	Add your company
Reports:	Biotechnology	Business Development	Management	Market & Sales	Medical Devices	Pharmaceuticals
Jobs:	Pharmaceutical jobs	Browse jobs	Search for jobs	Create your CV	Employer profiles	Post your jobs
Forums:	Talk to an expert	Industry Gossip	Business Development	What's new	Reports	Services
News:	Deals & Alliances	Development	Financial Results	Financings	Intellectual Property	Regulatory
Events:	Pharma events	Calendar	Organizers	Featured events	Search
Articles:	Business Development	Technologies	Events	Legal and regulatory	Therapeutic
Deals:	Industry Sector	Therapeutic Target	Deals Date	Search	Reports	Press releases
About us:	Our Audience	Case Studies	Newsletter	Careers	FAQ	Contact us